ClinicalTrials.gg
CompletedNCT05089708LEAPUpdated Dec 20, 2023Results posted

AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation

A Phase 4 interventional study of Trifarotene Cream and Trifarotene Vehicle Cream in Acne Vulgaris, sponsored by Galderma R&D. Completed at 25 sites in 2 countries. Open to participants aged 13 Years to 35 Years. Per ClinicalTrials.gov, last updated 2023-12-20.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
123
Allocation
Randomized
Ages
13 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing trifarotene in Acne Vulgaris — none open to participants now, 1 under way, 1 of them phase 3. trifarotene · Acne Vulgaris.

Enrollment
10th of 12
123 · median 507
Started
2021
with 1 other
Phase 4
3 of 12
none open now
Registered
8th of 12
by date
Lead sponsor
9 of 12
Galderma R&D

Among the 12 studies testing trifarotene in Acne Vulgaris, this one is the 10th largest by enrollment, is one of 2 that started in 2021, is one of 3 in phase 4, and was the 8th registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 94 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

None of the 12 studies testing trifarotene in Acne Vulgaris is open now. The open studies under Acne Vulgaris, anywhere →

About trifarotene

trifarotene: first FDA approval 2019 (AKLIEF). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 47 Acne Vulgaris studies recruiting now, 17 (36%) set no upper age limit and 29 (62%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 13 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing trifarotene in Acne Vulgaris as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of Trifarotene 50 microgram per gram (mcg/g) cream compared to its vehicle cream in the treatment of moderate acne vulgaris with risk of acne-induced post inflammatory hyperpigmentation (PIH) after 24 weeks of treatment in facial acne participants

03

Conditions studied

  • Acne Vulgaris

Browse trials for

Keywords

  • Acne vulgaris
  • Trifarotene
  • Aklief
  • CD5789
04

Who can participate

Ages eligible
13 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participant with clinical diagnosis of acne vulgaris, defined by:

    1. moderate acne on the face (acne Investigator's Global Assessment [IGA] =3); and
    2. with minimum of 20 inflammatory lesions and 25 non inflammatory lesions on the face (excluding the nose); and
    3. moderate to marked PIH on the face (Overview of Pigmentation Disorders hyperpigmentation scale 4-6); and
    4. no more than one acne nodule or cyst (greater than [>] 1 centimeter [cm]) on face (excluding the nose)
  • Participant with any Fitzpatrick Skin Type I to VI (target patient enrollment according to FST)
  • Female participants of must have a negative urine pregnancy test (UPT) at Baseline visit
  • Female participants of childbearing potential must agree to use an adequate and approved method of throughout the study
  • Female participant of non-childbearing potential
  • Other protocol defined inclusion criteria could apply

Key Exclusion Criteria:

  • Participant with severe acne (IGA > 3)
  • Participant with more than 1 nodule/cyst on the face (excluding the nose)
  • Participant with acne conglobata, acne fulminans, secondary acne, nodulocystic acne, acne requiring systemic treatment
  • Participant with damaged facial skin that may interfere with study assessments
  • Female participant who is pregnant, lactating or planning a pregnancy during the study
  • Female participant of childbearing potential using combined oral contraceptives approved as acne treatments, in whom the dose has not been stable for at least 6 months prior to the Baseline visit
  • Participant with known impaired hepatic or renal functions
  • Participant with active or chronic skin allergies
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
123 participants (actual)

Study arms

  • Experimental
    Trifarotene (CD5789) 50 mcg/g Cream

    Drug: Trifarotene Cream

  • Placebo comparator
    Trifarotene Vehicle Cream

    Drug: Trifarotene Vehicle Cream

Interventions

  • Participants will apply a thin a layer of trifarotene (CD5789) 50 mcg/g cream on the face once daily, in the evening for 24 weeks

    Also known as: Aklief

  • DrugTrifarotene Vehicle Cream

    Participants will apply a thin a layer of trifarotene vehicle cream on the face once daily, in the evening for 24 weeks

06

What researchers measure

Primary outcomes

  1. Absolute Change From Baseline in Post-Inflammatory Hyperpigmentation (PIH) Overall Disease Severity (ODS) Scores at Week 24

    The PIH ODS Score is based on a 9-point scale: Grade 0 Normal; Grade 1 Present, but \<mild; Grade 2 Mild (slightly noticeable); Grade 3 Between mild and moderate; Grade 4 Moderate; Grade 5 Between moderate and marked; Grade 6 Marked (distinctive); Grade 7 Between marked and severe; Grade 8 Severe (very distinctive). A negative change indicates a reduction from in PIH disease severity score from baseline.

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Percent Change From Baseline in PIH ODS Scores at Week 24

    The PIH ODS Score is based on a 9-point scale: Grade 0 Normal; Grade 1 Present, but \<mild; Grade 2 Mild (slightly noticeable); Grade 3 Between mild and moderate; Grade 4 Moderate; Grade 5 Between moderate and marked; Grade 6 Marked (distinctive); Grade 7 Between marked and severe; Grade 8 Severe (very distinctive). A negative change indicates a reduction from in PIH disease severity score from baseline.

    Time frame: Baseline and Week 24

  2. Absolute Change From Baseline in PIH ODS Scores at Weeks 12, 16 and 20

    The PIH ODS Score is based on a 9-point scale: Grade 0 Normal; Grade 1 Present, but \<mild; Grade 2 Mild (slightly noticeable); Grade 3 Between mild and moderate; Grade 4 Moderate; Grade 5 Between moderate and marked; Grade 6 Marked (distinctive); Grade 7 Between marked and severe; Grade 8 Severe (very distinctive). A negative change indicates a reduction from in PIH disease severity score from baseline.

    Time frame: Baseline, at Week 12, Week 16 and Week 20

  3. Percent Change From Baseline in PIH Overall Disease Severity Scores at Weeks 12, 16 and 20

    The PIH ODS Score is based on a 9-point scale: Grade 0 Normal; Grade 1 Present, but \<mild; Grade 2 Mild (slightly noticeable); Grade 3 Between mild and moderate; Grade 4 Moderate; Grade 5 Between moderate and marked; Grade 6 Marked (distinctive); Grade 7 Between marked and severe; Grade 8 Severe (very distinctive). A negative change indicates a reduction from in PIH disease severity score from baseline.

    Time frame: Baseline, at Week 12, Week 16 and Week 20

07

Results

Posted Dec 20, 2023

Participant flow

The study was conducted at 18 investigational centers in the United States and Spain from 22 Dec 2021 to 15 Dec 2022.

Participant flow — Overall Study
MilestoneTrifarotene (CD5789) CreamTrifarotene Vehicle Cream
Started6063
Completed4553
Not completed1510
Withdrew: Lost to follow-up97
Withdrew: Withdrawal by subject31
Withdrew: Non-compliance with investigational product11
Withdrew: Withdrawal by parent or guardian21

Outcome measures

PrimaryAbsolute Change From Baseline in Post-Inflammatory Hyperpigmentation (PIH) Overall Disease Severity (ODS) Scores at Week 24

The PIH ODS Score is based on a 9-point scale: Grade 0 Normal; Grade 1 Present, but \<mild; Grade 2 Mild (slightly noticeable); Grade 3 Between mild and moderate; Grade 4 Moderate; Grade 5 Between moderate and marked; Grade 6 Marked (distinctive); Grade 7 Between marked and severe; Grade 8 Severe (very distinctive). A negative change indicates a reduction from in PIH disease severity score from baseline.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · score on a scale
Absolute Change From Baseline in Post-Inflammatory Hyperpigmentation (PIH) Overall Disease Severity (ODS) Scores at Week 24
score on a scaleTrifarotene (CD5789) CreamTrifarotene Vehicle Cream
Absolute Change From Baseline in Post-Inflammatory Hyperpigmentation (PIH) Overall Disease Severity (ODS) Scores at Week 24-2.1 ± 0.27-2.1 ± 0.24
SecondaryPercent Change From Baseline in PIH ODS Scores at Week 24

The PIH ODS Score is based on a 9-point scale: Grade 0 Normal; Grade 1 Present, but \<mild; Grade 2 Mild (slightly noticeable); Grade 3 Between mild and moderate; Grade 4 Moderate; Grade 5 Between moderate and marked; Grade 6 Marked (distinctive); Grade 7 Between marked and severe; Grade 8 Severe (very distinctive). A negative change indicates a reduction from in PIH disease severity score from baseline.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in PIH ODS Scores at Week 24
Percent changeTrifarotene (CD5789) CreamTrifarotene Vehicle Cream
Percent Change From Baseline in PIH ODS Scores at Week 24-45.4 ± 5.73-44.9 ± 5.18
SecondaryAbsolute Change From Baseline in PIH ODS Scores at Weeks 12, 16 and 20

The PIH ODS Score is based on a 9-point scale: Grade 0 Normal; Grade 1 Present, but \<mild; Grade 2 Mild (slightly noticeable); Grade 3 Between mild and moderate; Grade 4 Moderate; Grade 5 Between moderate and marked; Grade 6 Marked (distinctive); Grade 7 Between marked and severe; Grade 8 Severe (very distinctive). A negative change indicates a reduction from in PIH disease severity score from baseline.

Time frame:
Baseline, at Week 12, Week 16 and Week 20
Reported as:
Least squares mean · score on a scale
Absolute Change From Baseline in PIH ODS Scores at Weeks 12, 16 and 20
score on a scaleTrifarotene (CD5789) CreamTrifarotene Vehicle Cream
Absolute change at Week 12-1.6 ± 0.18-1.1 ± 0.17
Absolute change at Week 16-1.9 ± 0.2-1.7 ± 0.19
Absolute change at Week 20-2.0 ± 0.22-1.9 ± 0.21
SecondaryPercent Change From Baseline in PIH Overall Disease Severity Scores at Weeks 12, 16 and 20

The PIH ODS Score is based on a 9-point scale: Grade 0 Normal; Grade 1 Present, but \<mild; Grade 2 Mild (slightly noticeable); Grade 3 Between mild and moderate; Grade 4 Moderate; Grade 5 Between moderate and marked; Grade 6 Marked (distinctive); Grade 7 Between marked and severe; Grade 8 Severe (very distinctive). A negative change indicates a reduction from in PIH disease severity score from baseline.

Time frame:
Baseline, at Week 12, Week 16 and Week 20
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in PIH Overall Disease Severity Scores at Weeks 12, 16 and 20
Percent changeTrifarotene (CD5789) CreamTrifarotene Vehicle Cream
Percent Change at Week 12-34.4 ± 3.78-23.6 ± 3.60
Percent Change at Week 16-41.2 ± 4.35-36.1 ± 4.17
Percent Change at Week 20-43.9 ± 4.83-41.0 ± 4.75

Adverse events

Collected over Adverse events were assessed from screening up to Week 24. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trifarotene (CD5789) Cream0/60 (0%)0/60 (0%)10/60 (16.7%)
Trifarotene Vehicle Cream0/63 (0%)1/63 (1.6%)19/63 (30.2%)
Most frequent serious events
Most frequent serious events
EventTrifarotene (CD5789) CreamTrifarotene Vehicle Cream
Bipolar DisorderPsychiatric disorders0/601/63
Most frequent other events
Showing 10 of 22
Most frequent other events
EventTrifarotene (CD5789) CreamTrifarotene Vehicle Cream
COVID-19Infections and infestations3/606/63
InfluenzaInfections and infestations2/601/63
NasopharyngitisInfections and infestations2/601/63
HeadachedNervous system disorders0/602/63
DysmenorrhoeaReproductive system and breast disorders0/602/63
VomitingGastrointestinal disorders1/600/63
Attention deficit hyperactivity disorderPsychiatric disorders1/600/63
Oropharyngeal painRespiratory, thoracic and mediastinal disorders1/601/63
Muscle spasmsMusculoskeletal and connective tissue disorders1/600/63
Bacterial vaginosisInfections and infestations0/601/63

Baseline characteristics

Age, Continuous
Age, Continuous(years)Trifarotene (CD5789) CreamTrifarotene Vehicle CreamTotal
Mean22.7 ± 6.3021.9 ± 5.9522.3 ± 6.11
Sex: Female, Male
Sex: Female, Male(Participants)Trifarotene (CD5789) CreamTrifarotene Vehicle CreamTotal
Female454893
Male151530
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Trifarotene (CD5789) CreamTrifarotene Vehicle CreamTotal
Hispanic or Latino212748
Not Hispanic or Latino393675
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Trifarotene (CD5789) CreamTrifarotene Vehicle CreamTotal
American Indian or Alaska Native101
Asian11617
Native Hawaiian or Other Pacific Islander022
Black or African American222345
White253156
More than one race000
Unknown or Not Reported112
08

Study locations

25 sites
  • Galderma Investigational Site #8636
    Fountain Valley, California 92708, United States
  • Galderma Investigational Site #8224
    Fremont, California 94538, United States
  • Galderma Investigational Site #8358
    San Diego, California 92108, United States
  • Galderma Investigational Site #9955
    San Diego, California 92123, United States
  • Galderma Investigational Site #7012
    Lutz, Florida 33549, United States
  • Galderma Investigational Site #8184
    Maitland, Florida 32751, United States
  • Galderma Investigational Site #8764
    Tampa, Florida 33613, United States
  • Galderma Investigational Site #9950
    Evansville, Indiana 47714, United States
  • Galderma Investigational Site #9952
    Baton Rouge, Louisiana 70808, United States
  • Galderma Investigational Site #8606
    New Orleans, Louisiana 70115, United States
  • Galderma Investigational Site #8012
    Glenn Dale, Maryland 20769, United States
  • Galderma Investigational Site #9948
    Hyattsville, Maryland 20782, United States
  • Galderma Investigational Site #8554
    Detroit, Michigan 48202, United States
  • Galderma Investigational Site #8108
    Las Vegas, Nevada 89148, United States
  • Galderma Investigational Site #8620
    New York, New York 10025, United States
  • Galderma Investigational Site #9956
    New York, New York 10025, United States
  • Galderma Investigational Site #9949
    New York, New York 10155, United States
  • Galderma Investigational Site #9953
    Tulsa, Oklahoma 74133, United States
  • Galderma Investigational Site #8207
    Nashville, Tennessee 37215, United States
  • Galderma Investigational Site #9920
    Arlington, Texas 76011, United States
  • Galderma Investigational Site #8329
    San Antonio, Texas 78229, United States
  • Galderma Investigational Site #8433
    San Antonio, Texas 78229, United States
  • Galderma Investigational Site #6192
    Zaragoza, Aragon 50009, Spain
  • Galderma Investigational Site #6278
    Manises, Valencia 46940, Spain
  • Galderma Investigational Site #6277
    Pontevedra, 36071, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Dec 2022, 11 months.

Results were first posted in Dec 2023, 1 year after primary completion.

Of 45 phase 4 interventional studies under Acne Vulgaris, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's 11 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2021
First posted
Oct 22, 2021
StartActual
Dec 22, 2021
Primary completionActual
Dec 15, 2022
CompletionActual
Dec 15, 2022
Results first posted
Dec 20, 2023
Last update
Dec 20, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05089708
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Oct 22, 2021
Start date
Dec 22, 2021
Primary completion
Dec 15, 2022
Completion
Dec 15, 2022
Results posted
Dec 20, 2023
Last update
Dec 20, 2023

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trifarotene

Start the discussion